

The Effect of Hemodiafiltration on Sclerostin level and bone specific alkaline phosphatase in Comparison to High Flux dialysis

Thesis

submitted for partial fulfillment of the MD degree in internal medicine

By

Marwa Shaaban Abd El Samea

M.B.B.CH, MSc

Faculty of Medicine Ain Shams University

Under supervision of

Prof. Dr. Hesham Mohamed El Sayed

Professor of Internal Medicine and Nephrology

Faculty of Medicine_ Ain Shams University

Prof. Dr. Magdy Mohamed El Sharkawy

Professor of Internal Medicine and Nephrology

Faculty of Medicine_ Ain Shams University

Dr. Cherry Reda kamel

Assistant Professor of Internal Medicine and Nephrology

Faculty of Medicine_ Ain Shams University

Dr. Hussein Sayed Hussein

Assistant Professor of Internal Medicine & Nephrology

Faculty of Medicine_ Ain Shams University

Dr. Mostafa Abdel Nasier Abdel Gawad

Lecturer of Internal Medicine & Nephrology

Faculty of Medicine_ Ain Shams University

**Faculty of Medicine
Ain Shams University**

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبب انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم الكبير

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgement

First of all, all gratitude is due to **God** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

Really I can hardly find the words to express my gratitude to **Prof. Dr. Hesham Mohamed El Sayed and Prof. Dr. Magdy Mohamed El Sharkawy**; Professors of Internal Medicine, faculty of medicine, Ain Shams University, for their supervision, continuous help, encouragement throughout this work and tremendous effort they had done in the meticulous revision of the whole work. It is a great honor to work under their guidance and supervision.

I owe much to **Dr. Walid Tahahead** of nephrology department at Maadi Military Hospital for his continues help, valuable suggestions and patience throughout the whole work.

I owe much to **Dr. Cherry Reda Kamel and Dr. Hussein Sayed Hussein**; Assistant Professors of Internal Medicine faculty of medicine, Ain Shams University, for their continues help, valuable suggestions and patience throughout the whole work.

I owe much to **Dr. Mostafa Abdel Nasier Abdel Gawad**; Lecturer of Internal Medicine faculty of medicine, Ain Shams University, for his continues help throughout the whole work.

Last but not least, I dedicate this work to my **family** and **friends** whom without their sincere emotional support, pushing me forward this work would not have ever been completed.

CONTENTS

	Page
Acknowledgment	--
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Work.....	5
Review of Literature	6
Chapter 1: Bone mineral disease and chronic kidney disease patients.....	6
Chapter 2: New biomarkers in Bone mineral disease ...	25
Chapter 3: Online Haemodiafiltration	42
Patients and Methods.....	51
Results.....	57
Discussion	94
Summary and Conclusion	104
Recommendations	107
References	108
Arabic Summary	--

List of Abbreviations

1, 25-OH ₂ -D ₃	: 1, 25-dihydroxyvitamin D
AGE	: Advanced glycation end products
ALP	: Alkaline phosphatase
BFR ₀	: Bone formation rate
BMD	: Bone mineral density
BMI	: Body mass index
BS-AP	: Bone specific alkaline phosphatase
Ca	: Calcium
CatK	: Cathepsin K
CKD	: Chronic kidney disease
CKD-MBD	: Chronic kidney disease-mineral and bone disorder
CRP	: C-reactive protein
CVD	: Cardiovascular disease
DA	: Dialysis amyloidosis
DEXA	: Dual-energy X-ray absorptiometry
DF	: Dialysate flow
Dkk-1	: Dickkopf -1
DPD	: Deoxypyridinoline
ELISA	: Enzyme-linked immunosorbent assay
ESRD	: End-stage renal disease
FGF-23	: Fibroblast growth factor 23
FGFR1	: Fibroblast growth factor receptor one
GFR	: Glomerular filtration rate
GPI	: Glycosylphosphatidylinositol
HCV	: Hepatitis c virus
HD	: Hemodialysis
HDF	: Hemodiafiltration
HGB	: Hemoglobin

List of Abbreviations (Cont.)

ICTP	: C-terminal telopeptides of type I collagen
IQR	: Interquartile range
JIA	: Juvenile idiopathic arthritis
LMWP	: Low-molecular-weight protein
LRP	: Lipoprotein receptor-related protein
LVH	: Left ventricular hypertrophy
M	: Male
MiRNAs	: Micro RNAs
OA	: Osteoarthritis
OC	: Osteocalcin
OL-HDF	: Online hemodiafiltration
OPG	: Osteoprotegerin
PICP	: Procollagen type I carboxy-terminal extension peptide
Po4	: Phosphorus
PTH	: Parathyroid hormone
PYD	: Pyridinoline
RA	: Rheumatoid arthritis
RLS	: Restless legs syndrome
β2-m	: Beta2-microglobulin
sScl	: Serum sclerostin
SsRNAs	: Single-stranded RNAs
TIBC	: Total iron binding capacity
TMP	: Transmembrane pressure
TNFα	: Tumor necrosis factor alpha
TRAP	: Tartrate-resistant acid phosphatase
U test	: Mann Whitney Test
UF	: Ultra filtration
Wnt pathway	: Wntless pathway

LIST OF TABLES

Table	Title	Page
1	Histological classification of renal osteodystrophy.	20
2	Recommended target serum values of the biochemical markers in CKD patients.	24
3	The classical biochemical markers of bone turnover.	29
4	The potential new bone markers.	30
5	Modes of hemodiafiltration.	45
6	Comparison between the two studied groups according to demographic data.	57
7	Comparison between the two studied groups according to etiology of ESRD.	60
8	Comparison between the two studied groups according to duration of HD.	61
9	Comparison between the two studied groups according to HCV and vascular access.	62
10	Comparison between the two studied groups according to different dialysis parameters.	63
11	Comparison between the two studied groups according to blood pressure.	64
12	Comparison between the two studied groups according to type of filter.	65
13	Comparison between the two studied groups according to iron profile and hemoglobin level.	66

Table	Title	Page
14	Comparison between the two studied groups according to urea.	68
15	Comparison between the two studied groups according to serum calcium, corrected serum calcium (mg/dl), serum albumin and calcium supplement.	70
16	Comparison between the two studied groups according to PO ₄ (mg/dl), Ca × PO ₄ , intact PTH and VIT D treatment.	74
17	Comparison between the two studied groups according to alkaline phosphatase..	77
18	Comparison between the two studied groups according to sclerostin prestudy.	79
19	Comparison between the two studied groups according to BS-AP prestudy.	81
20	Descriptive analysis of the studied cases according to Sclerostin and BS-AP post 3months in group A.	83
21	Comparison between the two studied groups (high flux, HDF post study) as regard sclerostin and BS-AP pre session.	85
22	Comparison between pre/post study HDF group as regard sclerostin, BS-AP pre session.	87
23	Comparison between the two studied groups according to sclerostin and BS-AP (Reduction ratio) (pre/post three months in group A).	88

Table	Title	Page
24	Correlation between Sclerostin delta change and different parameters in each group.	91
25	Comparison between the two studied groups according to HGB (gm/dl) (pre/post three months in group A).	92

LIST OF FIGURES AND CHARTS

Fig.	Title	Page
1	Factors that lead to over activity of parathyroid gland.	10
2	Number of factors contributes to a relative state of hypoparathyroidism.	16
3	Bone disease and soft tissue calcification.	19
4	Stages of bone remodeling.	26
5	Mean plasma intact PTH, 1, 25(OH) 2D3 and FGF23 concentrations in patients with different degree of CKD.	27
6	Vascular smooth muscles cells undergo osteo/chondrogenic transdifferentiation in a pro-calcifying environment.	33
7	Comparison between the two studied groups according to Sex.	58
8	Comparison between the two studied groups according to Age (years).	59
9	Comparison between the two studied groups according to Dry weight (kg).	59
10	Comparison between the two studied groups according to BMI (kg/cm ²).	60
11	Comparison between the two studied groups according to etiology of risk factors.	61
12	Comparison between the two studied groups according to duration of HD.	62
13	Comparison between the two studied groups according to Dialysate flow.	64

Fig.	Title	Page
14	Comparison between the two studied groups according to blood pressure.	65
15	Comparison between the two studied groups according to Serum iron ($\mu\text{g}/\text{dl}$).	67
16	Comparison between the two studied groups according to TSAT (%).	67
17	Comparison between the two studied groups according to Urea (mg/dl) pre /post dialysis.	69
18	Comparison between the two studied groups according to urea Reduction ratio (%).	69
19	Comparison between the two studied groups according to serum calcium.	72
20	Comparison between the two studied groups according to corrected serum calcium (mg/dl).	72
21	Comparison between the two studied groups according to serum albumin.	73
22	Comparison between the two studied groups according to PO_4 (mg/dl).	76
23	Comparison between the two studied groups according to $\text{Ca} \times \text{PO}_4$ product.	76
24	Comparison between the two studied groups according to intact PTH.	77
25	Comparison between the two studied groups according to total alkaline phosphatase.	78

Fig.	Title	Page
26	Comparison between the two studied groups according to Sclerostin (pg/ml) prestudy pre/post dialysis	80
27	Comparison between the two studied groups according to Sclerostin prestudy Reduction ratio.	80
28	Comparison between the two studied groups according to BS-AP prestudy (ng/l) pre/post dialysis.	82
29	Comparison between the two studied groups according to BS-AP reduction ratio prestudy.	82
30	Descriptive analysis of the studied cases according to Sclerostin post 3months in group A.	84
31	Descriptive analysis of the studied cases according to BS-AP post 3months in group A.	84
32	Comparison between the two studied groups according to sclerostin pre session (post study in group A).	86
33	Comparison between the two studied groups according to BS-AP pre session(post study in group A).	86
34	Comparison between pre/post study in HDF group as regard sclerostin pre session.	87

Fig.	Title	Page
35	Comparison between pre/post study in HDF group as regard BS-AP pre session.	88
36	Comparison between the two studied groups as regard sclerostin reduction ratio.	90
37	Comparison between the two studied groups as regard BS-AP reduction ratio.	90
38	Relation between sclerostin delta change (pre/post study) and HGB change.	92
39	Comparison between the two studied groups as regard HGB level (pre/post study in HDF group).	93

INTRODUCTION

Chronic kidney disease (CKD) is a pandemic affecting >10% of the Western population. CKD is associated with high rates of cardiovascular mortality. CKD also confers an increased fracture risk. Patients with an estimated glomerular filtration rate of <60ml/min had a twofold increased risk of hip fracture. The risk for fractures further increases up to four fold in dialysis patients as compared with age and gender matched non-CKD individuals (**Naylor et al., 2014**).

Vascular calcification and bone disorders are entitled chronic kidney disease-mineral and bone disorder (CKD-MBD) which contributes to increased morbidity and mortality in CKD patients. The mechanisms causing the CKD-MBD syndrome are associated with the stimulation of osteocyte secretion (**Kooman et al., 2014**).

Although several biomarkers of CKD-MBD, such as calcium, phosphate, parathyroid hormone (PTH predict outcome in end-stage renal disease (ESRD), there is a need of a biomarker that could predict the presence and extent of vascular calcification and bone disorders (**Drechsler et al., 2011**).

Sclerostin is a new and potentially important player in the well-known bone–vascular axis in chronic kidney disease (CKD) and end-stage renal disease. Sclerostin, a 22-kDa protein secreted by osteocytes and chondrocytes. Sclerostin was found to be a potent inhibitor of bone formation.

Osteocytes effectively act as mechanoreceptors for bone formation, and sclerostin was shown to play a key role in the development of osteoporosis (**Pierre et al., 2015**).

Sclerostin is the product of the SOST gene, which was discovered in 2001. Inactivating mutations of the SOST gene have been associated with sclerosteosis, a high bone mass phenotype. Sclerostin is a Wnt signaling pathway antagonist that results in negative regulation of bone formation by repressing differentiation and proliferation of osteoblasts (**Rocheft et al., 2010**).

Sclerostin, an osteocyte-derived glycoprotein acts as a soluble inhibitor of the Wnt signaling pathway and its physiological role is to reduce bone formation. The serum sclerostin levels increase with the progression of CKD (**Fang et al., 2014**).

In patients undergoing maintenance dialysis, sclerostin has been reported to be increased and associated with bone quality impairment (**Cejka et al., 2012**).

Circulating sclerostin levels correlate negatively with serum PTH levels in both the general population and dialysis patients. High levels of PTH and sclerostin coexist in CKD. This observation raises the suspicion that sclerostin contributes to the well-known PTH resistance in CKD (**Cejka et al., 2011**).

As sclerostin expression is decreased by mechanical loading of the skeleton, low physical activity in patients with